title: MYH9 genetic variants associated with glomerular disease: what is the role for genetic testing?
abstract: Genetic variation in MYH9, encoding nonmuscle myosin IIA heavy chain, has been associated recently with increased risk for kidney disease. Previously, MYH9 missense mutations have been shown to cause the autosomal-dominant MYH9 (ADM9) spectrum, characterized by large platelets, leukocyte Döhle bodies, and, variably, sensorineural deafness, cataracts, and glomerulopathy. Genetic testing is indicated for familial and sporadic cases that fit this spectrum. By contrast, the MYH9 kidney risk variant is characterized by multiple intronic single nucleotide polymorphisms, but the causative variant has not been identified. Disease associations include human immunodeficiency virus-associated collapsing glomerulopathy, focal segmental glomerulosclerosis, hypertension-attributed end-stage kidney disease, and diabetes-attributed end-stage kidney disease. One plausible hypothesis is that the MYH9 kidney risk variant confers a fragile podocyte phenotype. In the case of hypertension-attributed kidney disease, it remains unclear if the hypertension is a contributing cause or a consequence of glomerular injury. The MYH9 kidney risk variant is strikingly more common among individuals of African descent, but only some will develop clinical kidney disease in their lifetime. Thus, it is likely that additional genes and/or environmental factors interact with the MYH9 kidney risk variant to trigger glomerular injury. A preliminary genetic risk stratification scheme, using two single nucleotide polymorphisms, may estimate lifetime risk for kidney disease. Nevertheless, at present, no role has been established for genetic testing as part of personalized medicine, but testing should be considered in clinical studies of glomerular diseases among populations of African descent. Such studies will address critical questions pertaining to MYH9-associated kidney disease, including mechanism, course, and response to therapy.
authors.affiliation: Kidney Disease Section, Kidney Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892-1268, USA. jbkopp@nih.gov
authors.forename: Jeffrey B
authors.initials: JB
authors.lastname: Kopp
authors.forename: Cheryl A
authors.initials: CA
authors.lastname: Winkler
authors.forename: George W
authors.initials: GW
authors.lastname: Nelson
mesh_terms: D016263:AIDS-Associated Nephropathy / Q000175:diagnosis / Q000235:genetics*; D000075944:Apolipoprotein L1; D001053:Apolipoproteins / Q000235:genetics; D044383:Black People / Q000235:genetics; D005820:Genetic Testing; D005838:Genotype; D005923:Glomerulosclerosis, Focal Segmental / Q000175:diagnosis / Q000235:genetics; D006801:Humans; D007676:Kidney Failure, Chronic / Q000175:diagnosis / Q000208:ethnology / Q000235:genetics*; D008075:Lipoproteins, HDL / Q000235:genetics; D020409:Molecular Motor Proteins / Q000235:genetics*; D018995:Myosin Heavy Chains / Q000235:genetics*; D016017:Odds Ratio; D020641:Polymorphism, Single Nucleotide; D012306:Risk
chemical_list: C108666:APOL1 protein, human; D000075944:Apolipoprotein L1; D001053:Apolipoproteins; D008075:Lipoproteins, HDL; C103814:MYH9 protein, human; D020409:Molecular Motor Proteins; D018995:Myosin Heavy Chains
references.citation: Clin Infect Dis. 2005 Jun 1;40(11):1559-85
references.pmid: 15889353
references.citation: Kidney Int. 2009 Apr;75(7):736-45
references.pmid: 19177153
references.citation: N Engl J Med. 1989 Sep 7;321(10):625-30
references.pmid: 2770791
references.citation: Nat Rev Mol Cell Biol. 2009 Nov;10(11):778-90
references.pmid: 19851336
references.citation: Am J Nephrol. 2009;29(6):626-32
references.pmid: 19153477
references.citation: Hum Mol Genet. 2010 May 1;19(9):1805-15
references.pmid: 20124285
references.citation: Science. 2009 Nov 27;326(5957):1208-12
references.pmid: 19965462
references.citation: J Natl Cancer Inst. 1993 Jun 2;85(11):892-7
references.pmid: 8492317
references.citation: Nephrol Dial Transplant. 2009 Nov;24(11):3366-71
references.pmid: 19567477
references.citation: Am J Physiol Renal Physiol. 2008 Oct;295(4):F959-70
references.pmid: 18684887
references.citation: Science. 2010 Aug 13;329(5993):841-5
references.pmid: 20647424
references.citation: J Am Soc Nephrol. 2005 Apr;16(4):1061-8
references.pmid: 15716334
references.citation: Am J Kidney Dis. 2003 Jan;41(1):95-104
references.pmid: 12500226
references.citation: Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3681-6
references.pmid: 16505385
references.citation: J Am Soc Nephrol. 2006 Jan;17(1):66-76
references.pmid: 16280470
references.citation: Semin Nephrol. 2003 Mar;23(2):172-82
references.pmid: 12704577
references.citation: Nat Genet. 2008 Oct;40(10):1175-84
references.pmid: 18794856
references.citation: Nat Genet. 2008 Oct;40(10):1185-92
references.pmid: 18794854
references.citation: Medicine (Baltimore). 2003 May;82(3):203-15
references.pmid: 12792306
references.citation: Cancer Causes Control. 1996 Sep;7(5):544-52
references.pmid: 8877053
references.citation: Am J Kidney Dis. 2000 May;35(5):884-8
references.pmid: 10793023